The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis.

Amphiregulin / metabolism Animals Bile Acids and Salts / biosynthesis Cholestasis, Intrahepatic / metabolism Cholesterol 7-alpha-Hydroxylase / metabolism ErbB Receptors / metabolism Humans Mice, Inbred C57BL

Journal

Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946

Informations de publication

Date de publication:
04 2019
Historique:
received: 29 05 2018
accepted: 26 10 2018
pubmed: 10 11 2018
medline: 30 5 2020
entrez: 10 11 2018
Statut: ppublish

Résumé

Intrahepatic accumulation of bile acids (BAs) causes hepatocellular injury. Upon liver damage, a potent protective response is mounted to restore the organ's function. Epidermal growth factor receptor (EGFR) signaling is essential for regeneration after most types of liver damage, including cholestatic injury. However, EGFR can be activated by a family of growth factors induced during liver injury and regeneration. We evaluated the role of the EGFR ligand, amphiregulin (AREG), during cholestatic liver injury and regulation of AREG expression by BAs. First, we demonstrated increased AREG levels in livers from patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). In two murine models of cholestatic liver injury, bile duct ligation (BDL) and alpha-naphthyl-isothiocyanate (ANIT) gavage, hepatic AREG expression was markedly up-regulated. Importantly, Areg

Identifiants

DOI: 10.1002/hep.30348 PMID: 30411380
pubmed: 30411380
doi: 10.1002/hep.30348
doi:

Substances chimiques

AREG protein, human 0
Amphiregulin 0
Areg protein, mouse 0
Bile Acids and Salts 0
Cholesterol 7-alpha-Hydroxylase EC 1.14.14.23
EGFR protein, human EC 2.7.10.1
EGFR protein, mouse EC 2.7.10.1
ErbB Receptors EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1632-1647

Subventions

Organisme : Instituto de Salud Carlos III
ID : FIS PI16/01126
Pays : International
Organisme : Instituto de Salud Carlos III
ID : PI16/00598
Pays : International
Organisme : Fundación La Caixa. Spain
ID : Hepacare
Pays : International
Organisme : BiO-Eusko Fundazioa, Spain
ID : BIO15/CA/011
Pays : International
Organisme : JUNTA DE CASTILLA Y LEON, SPAIN
ID : SA063P17
Pays : International
Organisme : Secretaría de Estado de Investigación, Desarrollo e Innovación
ID : SAF 2016-75972R
Pays : International

Informations de copyright

© 2018 by the American Association for the Study of Liver Diseases.

Auteurs

Eva Santamaría (E)

Hepatology Program, University of Navarra, Cima, Pamplona, Spain.
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.

Carlos M Rodríguez-Ortigosa (CM)

Hepatology Program, University of Navarra, Cima, Pamplona, Spain.
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Instituto de Investigaciones Sanitarias de Navarra-IdiSNA, Pamplona, Spain.

Iker Uriarte (I)

Hepatology Program, University of Navarra, Cima, Pamplona, Spain.
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.

Maria U Latasa (MU)

Hepatology Program, University of Navarra, Cima, Pamplona, Spain.

Raquel Urtasun (R)

Hepatology Program, University of Navarra, Cima, Pamplona, Spain.

Gloria Alvarez-Sola (G)

Hepatology Program, University of Navarra, Cima, Pamplona, Spain.

Marina Bárcena-Varela (M)

Hepatology Program, University of Navarra, Cima, Pamplona, Spain.

Leticia Colyn (L)

Hepatology Program, University of Navarra, Cima, Pamplona, Spain.

Sara Arcelus (S)

Hepatology Program, University of Navarra, Cima, Pamplona, Spain.

Maddalen Jiménez (M)

Hepatology Program, University of Navarra, Cima, Pamplona, Spain.

Kathleen Deutschmann (K)

Gastroenterology, Hepatology and Infectious Diseases Clinic, University Hospital Düsseldorf, Medical Faculty Heinrich-Heine-University, Düsseldorf, Germany.

Ana Peleteiro-Vigil (A)

Experimental Hepatology and Drug Targeting (HEVEFARM), IBSAL, University of Salamanca, Salamanca, Spain.

Julian Gómez-Cambronero (J)

Department of Biochemistry and Molecular Biology, Wright State University School of Medicine, Dayton, OH.

Malgorzata Milkiewicz (M)

Department of Medical Biology, Pomeranian Medical University, Szczecin, Poland.

Piotr Milkiewicz (P)

Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland.
Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland.

Bruno Sangro (B)

CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Instituto de Investigaciones Sanitarias de Navarra-IdiSNA, Pamplona, Spain.
Hepatology Unit, Navarra University Clinic, Pamplona, Spain.

Verena Keitel (V)

Gastroenterology, Hepatology and Infectious Diseases Clinic, University Hospital Düsseldorf, Medical Faculty Heinrich-Heine-University, Düsseldorf, Germany.

Maria J Monte (MJ)

CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Experimental Hepatology and Drug Targeting (HEVEFARM), IBSAL, University of Salamanca, Salamanca, Spain.

Jose J G Marin (JJG)

CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Experimental Hepatology and Drug Targeting (HEVEFARM), IBSAL, University of Salamanca, Salamanca, Spain.

Maite G Fernández-Barrena (MG)

Hepatology Program, University of Navarra, Cima, Pamplona, Spain.
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.

Matias A Ávila (MA)

Hepatology Program, University of Navarra, Cima, Pamplona, Spain.
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Instituto de Investigaciones Sanitarias de Navarra-IdiSNA, Pamplona, Spain.

Carmen Berasain (C)

Hepatology Program, University of Navarra, Cima, Pamplona, Spain.
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Instituto de Investigaciones Sanitarias de Navarra-IdiSNA, Pamplona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Protéines de la famille de l'EGF › Amphiréguline › The Epidermal Growth Factor Receptor Ligand...
questionsmedicales.fr › Eucaryotes › Animaux › The Epidermal Growth Factor Receptor Ligand...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Acides et sels biliaires › The Epidermal Growth Factor Receptor Ligand...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Cholestase intrahépatique › The Epidermal Growth Factor Receptor Ligand...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Cytochromes › Cytochrome P-450 enzyme system › Steroid hydroxylases › Cholesterol 7-alpha-hydroxylase › The Epidermal Growth Factor Receptor Ligand...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs ErbB › The Epidermal Growth Factor Receptor Ligand...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Epidermal Growth Factor Receptor Ligand...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › The Epidermal Growth Factor Receptor Ligand...